Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q2 2017 · 10-Q
Revenue$3.74K$3.74K−66.7% vs Q2 2016 Net Income-$564.74K-$564.74KN/M vs Q2 2016 EPS Diluted-$0.01-$0.01N/M vs Q2 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$468,609N/M Margins · derivedGross margin60.2%+67.7 pt vs Q2 2016
Operating margin-11697.4%−7325.2 pt vs Q2 2016
Net margin-15108.0%+1692.7 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 21, 2017 · 52 d after period end